Aclaris Therapeutics (ACRS) announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata. In this model of hair loss, conducted by Dr. Angela Christiano at Columbia University, ATI-2138 demonstrated rapid, near complete, and sustained hair regrowth compared to control and ritlecitinib.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052
- Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
- Aclaris advances ATI-052 after positive Phase 1a results
- Aclaris Therapeutics reports ‘positive’ results from Phase 1a trial of ATI-052
- Aclaris Therapeutics added to Nasdaq Biotechnology Index